Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Rhea-AI Summary

Aeterna Zentaris (NASDAQ: AEZS) announced that CEO Dr. Klaus Paulini will present at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be available on-demand from January 11, 2021, at 6:00 AM ET for registered attendees. Aeterna Zentaris specializes in biopharmaceuticals, focusing on therapeutics and diagnostic tests, notably their lead product, macimorelin, which is FDA and European Commission approved for diagnosing adult growth hormone deficiency. The company aims to expand macimorelin's market in various regions.

CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

The video webcast presentation will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (www.zentaris.com).

For more information about the event, please visit the conference website here.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen^™ through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments.

Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.

The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Asia and the rest of the world, in addition to other non-strategic assets to monetize their value. For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com

FAQ

When will Aeterna Zentaris present at the H.C. Wainwright BioConnect 2021 Conference?

Aeterna Zentaris will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021.

How can I watch the Aeterna Zentaris presentation at the conference?

The presentation will be available on-demand starting January 11, 2021, at 6:00 AM ET for registered attendees.

What is Aeterna Zentaris known for?

Aeterna Zentaris is known for its biopharmaceutical products, especially macimorelin, for diagnosing adult growth hormone deficiency.

Is macimorelin available in markets outside the U.S.?

Yes, Aeterna Zentaris is pursuing commercialization of macimorelin in Israel, Europe, and the UK through various agreements.

What is the significance of macimorelin for Aeterna Zentaris?

Macimorelin is the first oral test approved for diagnosing adult growth hormone deficiency, making it a key product for the company.